In vitro and in vivo evaluation of the Gelrite gellan gum-based ocular delivery system for indomethacin.

The poor bioavailability and therapeutic response exhibited by the conventional ophthalmic solutions due to pre-corneal elimination of the drug may be overcome by the use of in situ gel forming systems, which upon instillation as drops into the eye undergo a sol-gel transition in the cul-de-sac. This may result in better ocular availability of the drug. The purpose of this work was to develop an ophthalmic delivery system of the NSAID indomethacin, based on the concept of ion activated in situ gelation. Gelrite gellan gum, a novel ophthalmic vehicle, which gels in the presence of mono or divalent cations present in the lacrimal fluid, was used as the gelling agent. The developed formulations were therapeutically efficacious (in a uveitis induced rabbit eye model) and provided sustained release of the drug over an 8-hour period in vitro.

[1]  A. El-Kamel.  In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. , 2002, International journal of pharmaceutics.

[2]  S. Kant,et al.  In vitro and in vivo characterization of scleral implants of indomethacin. , 2001, Die Pharmazie.

[3]  P. Amin,et al.  Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Hong-Ru Lin,et al.  Carbopol/pluronic phase change solutions for ophthalmic drug delivery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Shulin Ding.  RECENT DEVELOPMENTS IN OPHTHALMIC DRUG DELIVERY , 1998 .

[6]  J. Blanchard,et al.  In vitro evaluation of pluronic F127-based controlled-release ocular delivery systems for pilocarpine. , 1998, Journal of pharmaceutical sciences.

[7]  P. Sado,et al.  Ophthalmic drug delivery systems—Recent advances , 1998, Progress in Retinal and Eye Research.

[8]  E. Lobel,et al.  A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye , 1997 .

[9]  E. Topp,et al.  Gellan-based systems for ophthalmic sustained delivery of methylprednisolone , 1993 .

[10]  James M. Hill,et al.  Corneal collagen shields for ocular delivery , 1993 .

[11]  P. Edman.  Biopharmaceutics of Ocular Drug Delivery , 1992 .

[12]  A. Mitra,et al.  Kinetics of aspirin hydrolysis in aqueous solutions and gels of poloxamines (Tetronic 1508)—Influence of microenvironment , 1991 .

[13]  T. Waaler,et al.  Rheological Characterization of Tear Substitutes , 1990 .

[14]  A. Rozier,et al.  Gelrite®: A novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol , 1989 .

[15]  D. Maurice.  Kinetics of Topically Applied Ophthalmic Drugs , 1987 .

[16]  R. Gurny,et al.  Ocular therapy with nanoparticulate systems for controlled drug delivery , 1985 .

[17]  Gordon L. Amidon,et al.  Thermodynamic studies on the gel-sol transition of some pluronic polyols , 1984 .

[18]  Susan C. Miller,et al.  Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits , 1982 .

[19]  N. J. Van Haeringen,et al.  Clinical biochemistry of tears , 1981 .

[20]  R. Gurny.  Preliminary study of prolonged acting drug delivery system for the treatment of glaucoma. , 1981, Pharmaceutica acta Helvetiae.